Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

BackgroundChemoradiotherapy alone is the standard treatment for locally advanced squamous cell anal carcinoma (SCAC). However, up to 50% of patients will experience recurrence; thus, there is a need for new treatments to improve outcomes. Modified docetaxel, cisplatin and 5-fluorouracil (mDCF) is a...

詳細記述

書誌詳細

主要な著者:	Stefano Kim, Jihane Boustani, Dewi Vernerey, Véronique Vendrely, Ludovic Evesque, Eric Francois, Laurent Quero, Francois Ghiringhelli, Christelle de la Fouchardière, Laëtitia Dahan, Oliver Bouché, Benoist Chibaudel, Farid El Hajbi, Chloé Vernet, Magali Rebucci-Peixoto, Alexandra Feuersinger, Christophe Maritaz, Christophe Borg
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2022-08-01
シリーズ:	Frontiers in Oncology
主題:	ezabenlimab squamous anal carcinoma modified Docetaxel Cisplatin 5-Fluorouracil (DCF)
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2022.918499/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!